Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Pledges $25 Mil. In Medicines To Asia

This article was originally published in The Pink Sheet Daily

Executive Summary

Relief organizations operating in the region affected by the earthquake and subsequent tsunami will also receive a $10 mil. donation, Pfizer says. Abbott is committing an aid package totaling $4 mil.

You may also be interested in...



Pfizer's McKinnell Cancels National Press Club Speech

Exec was expected to discuss health care reform, and was likely to have been asked about cardiovascular safety of Celebrex and Bextra. McKinnell canceled the speech due to the flu, which he caught in Asia while assessing Pfizer's tsunami relief efforts.

Pfizer's McKinnell Cancels National Press Club Speech

Exec was expected to discuss health care reform, and was likely to have been asked about cardiovascular safety of Celebrex and Bextra. McKinnell canceled the speech due to the flu, which he caught in Asia while assessing Pfizer's tsunami relief efforts.

Drug Company Contributions To Tsunami Relief Reach $62 Mil., PhRMA Says

Pharmaceutical Research & Manufacturers of America members have pledged to provide medicines, cash and services. The announcement is among the first from the group following the arrival of CEO Billy Tauzin. The Association of the British Pharmaceutical Industry quantified donations from specific companies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel